Lumakras
| Chemical Name | sotorasib |
| Dosage Form | Tablet (oral; 120 mg) |
| Drug Class | Inhibitors |
| System | Respiratory |
| Company | Amgen Inc. |
| Approval Year | 2021 |
Indication
- For the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.